# OnCo record paper-arrow-pralsetinib-gainor-lancet-oncol-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-arrow-pralsetinib-gainor-lancet-oncol-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-arrow-pralsetinib-gainor-lancet-oncol-2021" ;
  schema:name "ARROW: pralsetinib for RET fusion-positive non-small-cell lung cancer"@en ;
  schema:description "Pralsetinib, a second selective RET inhibitor, shrank tumours in 61 percent of previously treated and 70 percent of untreated patients with RET fusion-positive lung cancer, giving an alternative to selpercatinib."@en ;
  schema:url <https://onco.cc/key-papers/paper-arrow-pralsetinib-gainor-lancet-oncol-2021/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(21)00247-3>, <https://pubmed.ncbi.nlm.nih.gov/34118197/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(21)00247-3> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Gainor JF, Curigliano G, Kim DW, et al." ;
  onco:cancers <https://onco.cc/cancers/ret-fusion-nsclc/> ;
  onco:drugs <https://onco.cc/drugs/pralsetinib/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .